# A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

> **NCT00543569** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 323 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Alefacept
- **DRUG:** tacrolimus
- **DRUG:** basiliximab
- **DRUG:** mycophenolate mofetil
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00543569
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2015-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543569, "A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00543569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*